Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

About Us

Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.

read more

Vator Securities advises Immunovia on 70 MSEK Rights Issue

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

read more

Vator Securities advises ExpreS2ion on 60 MSEK Rights Issue

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines.

The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies.

read more

Vator Securities advises Scandion Oncology on 60 MSEK Rights Issue

Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.

Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.

read more

Vator Securities acts as Bookrunner in SciBase 33 MSEK Directed Issue and 15 MSEK Rights Issue

SciBase is a global medical technology company specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to increase diagnostic accuracy and ensure the prevention of skin diseases.

SciBase’s commitment is to minimize patient suffering, enable physicians to improve and save lives through rapid detection and intervention, and reduce healthcare costs.

read more

More News